Key strengths include a cash‑rich, debt‑free balance sheet that provides meaningful runway; a clear scientific focus around a novel target in a high‑need rare disease; and a history of being able to raise equity capital to support extensive R&D. The company has reduced financial risk from leverage and has aligned its strategy around a potentially first‑in‑class therapy with method‑of‑treatment IP and possible orphan‑drug advantages.

Major risks span science, regulation, finance, and reputation. Scientifically, the company has already experienced a high‑profile failure in Alzheimer’s and is concentrated in a single lead asset with unproven benefit in its new indication. Regulatorily, the full FDA clinical hold on the TSC trial is a critical obstacle, and its resolution is uncertain. Financially, Cassava is burning cash at an accelerating rate with no revenue, which implies ongoing dependence on external capital and continued shareholder dilution. Reputationally, allegations about past data integrity and ongoing litigation could weigh on partnerships, hiring, and market perception.

The overall outlook is highly uncertain and closely tied to a few pivotal events: resolving the FDA clinical hold, initiating the TSC proof‑of‑concept study, and ultimately demonstrating clear safety and efficacy for simufilam in TSC‑related epilepsy. In the meantime, the financial trajectory remains loss‑making, cash burn is substantial, and the balance sheet, while currently strong, will gradually weaken without new funding or a change in spending. For stakeholders, this is a high‑risk, high‑dependency profile where scientific and regulatory outcomes will likely dominate financial results over the next several years.